In vivo characterization of RC28-E, a fusion protein targeting VEGF and bFGF: Pharmacokinetics and ocular distribution in primates

Jiang, Jing; Kou, Xiangying; Liu, Zhihao; Huang, Min; Li, Hongzhen; Wu, Chuandong

doi:10.1016/j.exer.2019.107823

Cited by 8 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…133 Moreover, a novel molecule named RC-28-E, which works as a VEGF and basic fibroblast growth factor dual decoy receptor that inhibits not only the VEGF cascade but also basic fibroblast growth factor (bFGF, which stimulates VEGF expression), showed 3-day sustained release in primate models. 134,135 In the same way, developed RFP (DAVP2 and DAVP3) showed suppression of endothelial cell migration and proliferation and, inhibition of angiogenesis in a laser-induced choroidal neovascularization mouse model after intravitreal injections by inhibiting not only VEGF but also platelet-derived growth factor through suppression of the phosphorylation activation processes in the metabolic cascade. 138 Also, a collagen IV-derived peptide that acted by coupling to receptors of VEGF and platelet-derived growth factor, named "AXT 107", has been developed.…”

Section: De Veloping Molecule S and Ther Apie S For Tre Atment Of O Cul Ar Ang Iog Ene S Ismentioning

confidence: 81%

“…133 Moreover, a novel molecule named RC-28-E, which works as a VEGF and basic fibroblast growth factor dual decoy receptor that inhibits not only the VEGF cascade but also basic fibroblast growth factor (bFGF, which stimulates VEGF expression), showed 3-day sustained release in primate models. 134,135 In the same way, developed RFP (DAVP2 and DAVP3) showed variety of action and their adaptability according to the needs of patients. 142 Thus, there are DNA/RNA type molecules like a plasmidic DNA for uveitis treatment, 143 a small no coding RNA for retinopathies, 144 a small interference RNA for glaucoma, 145 and a supplemental DNA for retinopathies.…”

Section: Ta B L E 3 Developing Molecules and Therapies For Treatment mentioning

confidence: 85%

“…Novel molecules are continually being developed as alternative to anti-VEGF agents for ocular angiogenesis treatment including, primarily, RFP and peptides that act directly on the VEGF signaling pathways 132,133 and also inhibit ocular angiogenesis by other mechanisms not VEGF-related, like fibroblast growth factor, 134,135 matrix metalloproteinases, 136 and certain genes expression cascade. 137,138 Among this, it has been reported an insulin-like growth factor called CW-703, which showed suppression of endothelial cell PDGFRβ, platelet-derived growth factor receptor beta; PDR, proliferative diabetic retinopathy; VEGF, vascular endothelial growth factor; VEGFR1, vascular endothelial growth factor receptor 1; VEGFR2, vascular endothelial growth factor receptor 2.…”

Section: De Veloping Molecule S and Ther Apie S For Tre Atment Of Omentioning

confidence: 99%

“…Novel molecules are continually being developed as alternative to anti‐VEGF agents for ocular angiogenesis treatment including, primarily, RFP and peptides that act directly on the VEGF signaling pathways 132,133 and also inhibit ocular angiogenesis by other mechanisms not VEGF‐related, like fibroblast growth factor, 134,135 matrix metalloproteinases, 136 and certain genes expression cascade 137,138 …”

Section: Developing Molecules and Therapies For Treatment Of Ocular Amentioning

confidence: 99%

“…A recombinant adinopectin (cytokine) had an inhibiting effect on basal tube formation and migration comparable to the effect of bevacizumab in different endothelial cells by down regulating VEGF 133 . Moreover, a novel molecule named RC‐28‐E, which works as a VEGF and basic fibroblast growth factor dual decoy receptor that inhibits not only the VEGF cascade but also basic fibroblast growth factor (bFGF, which stimulates VEGF expression), showed 3‐day sustained release in primate models 134,135 …”

Section: Developing Molecules and Therapies For Treatment Of Ocular Amentioning

confidence: 99%

See 4 more Smart Citations

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Formica

Alfonso

Palma

2021

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Currently, biological drug therapy for ocular angiogenesis treatment is based on the administration of anti‐VEGF agents via intravitreal route. The molecules approved with this purpose for ocular use include pegaptanib, ranibizumab, and aflibercept, whereas bevacizumab is commonly off‐label used in the clinical practice. The schedule dosage involves repeated intravitreal injections of anti‐VEGF agents to achieve and maintain effective concentrations in retina and choroids, which are administrated as solutions form. In this review article, we describe the features of different anti‐VEGF agents, major challenges for their ocular delivery and the nanoparticles in development as delivery system of them. In this way, several polymeric and lipid nanoparticles are explored to load anti‐VEGF agents with the aim of achieving sustained drug release and thus, minimize the number of intravitreal injections required. The main challenges were focused in the loading the molecules that maintain their bioactivity after their release from nanoparticulate system, followed the evaluation of them through studies of formulation stability, pharmacokinetic, and efficacy in in vitro and in vivo models. The analysis was based on the information published in peer‐reviewed published papers relevant to anti‐VEGF treatments and nanoparticles developed as ocular anti‐VEGF delivery system.

show abstract

Section: De Veloping Molecule S and Ther Apie S For Tre Atment Of O Cul Ar Ang Iog Ene S Ismentioning

confidence: 81%

“…133 Moreover, a novel molecule named RC-28-E, which works as a VEGF and basic fibroblast growth factor dual decoy receptor that inhibits not only the VEGF cascade but also basic fibroblast growth factor (bFGF, which stimulates VEGF expression), showed 3-day sustained release in primate models. 134,135 In the same way, developed RFP (DAVP2 and DAVP3) showed variety of action and their adaptability according to the needs of patients. 142 Thus, there are DNA/RNA type molecules like a plasmidic DNA for uveitis treatment, 143 a small no coding RNA for retinopathies, 144 a small interference RNA for glaucoma, 145 and a supplemental DNA for retinopathies.…”

Section: Ta B L E 3 Developing Molecules and Therapies For Treatment mentioning

confidence: 85%

Section: De Veloping Molecule S and Ther Apie S For Tre Atment Of Omentioning

confidence: 99%

Section: Developing Molecules and Therapies For Treatment Of Ocular Amentioning

confidence: 99%

Section: Developing Molecules and Therapies For Treatment Of Ocular Amentioning

confidence: 99%

See 3 more Smart Citations

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Formica

Alfonso

Palma

2021

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases

Wu,

Li,

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Funduscopic diseases, including diabetic retinopathy (DR) and age‐related macular degeneration (AMD), significantly impact global visual health, leading to impaired vision and irreversible blindness. Delivering drugs to the posterior segment of the eye remains a challenge due to the presence of multiple physiological and anatomical barriers. Conventional drug delivery methods often prove ineffective and may cause side effects. Nanomaterials, characterized by their small size, large surface area, tunable properties, and biocompatibility, enhance the permeability, stability, and targeting of drugs. Ocular nanomaterials encompass a wide range, including lipid nanomaterials, polymer nanomaterials, metal nanomaterials, carbon nanomaterials, quantum dot nanomaterials, and so on. These innovative materials, often combined with hydrogels and exosomes, are engineered to address multiple mechanisms, including macrophage polarization, reactive oxygen species (ROS) scavenging, and anti‐vascular endothelial growth factor (VEGF). Compared to conventional modalities, nanomedicines achieve regulated and sustained delivery, reduced administration frequency, prolonged drug action, and minimized side effects. This study delves into the obstacles encountered in drug delivery to the posterior segment and highlights the progress facilitated by nanomedicine. Prospectively, these findings pave the way for next‐generation ocular drug delivery systems and deeper clinical research, aiming to refine treatments, alleviate the burden on patients, and ultimately improve visual health globally.

show abstract

Neuroinflammation and neovascularization in diabetic eye diseases (DEDs): identification of potential pharmacotherapeutic targets

et al. 2022

View full text Add to dashboard Cite

The goal of this review is to increase public knowledge of the etiopathogenesis of diabetic eye diseases (DEDs), such as diabetic retinopathy (DR) and ocular angiosarcoma (ASO), and the likelihood of blindness among elderly widows. A widow's life in North India, in general, is fraught with peril because of the economic and social isolation it brings, as well as the increased risk of death from heart disease, hypertension, diabetes, depression, and dementia. Neovascularization, neuroin ammation, and edema in the ocular tissue are hallmarks of the ASO, a rare form of malignant tumor. When diabetes, hypertension, and aging all contribute to increased oxidative stress, the DR can proceed to ASO. Microglia in the retina of the optic nerve head are responsible for causing in ammation, discomfort, and neurodegeneration.Those that come into contact with them will get blind as a result of this. Advanced glycation end products (AGE), vascular endothelial growth factor (VEGF), protein kinase C (PKC), poly-ADP-ribose polymerase (PARP), metalloproteinase9 (MMP9), nuclear factor kappaB (NFkB), program death ligand1 (PDL-1), factor VIII (FVIII), and von Willebrand factor (VWF) are potent agents for neovascularisation (NV), neuroin ammation and edema in the ocular tissue. AGE/VEGF, DAG/PKC, PARP/NFkB, RAS/VEGF, PDL-1/PD-1, VWF/FVIII/VEGF, and RAS/VEGF are all linked to the pathophysiology of DEDs. The interaction between NV and ASO is mostly determined by the VWF/FVIII/VEGF and PDL-1 /PD-1 axis. This study focused on retinoprotective medications that can pass the blood-retinal barrier and cure DEDs, as well as the factors that in uence the etiology of neovascularization and neuroin ammation in the eye.

show abstract

In vivo characterization of RC28-E, a fusion protein targeting VEGF and bFGF: Pharmacokinetics and ocular distribution in primates

Cited by 8 publications

References 21 publications

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases

Neuroinflammation and neovascularization in diabetic eye diseases (DEDs): identification of potential pharmacotherapeutic targets

Contact Info

Product

Resources

About